全國服務(wù)咨詢熱線：
18438616290
<b id="grzca"><menuitem id="grzca"></menuitem></b>
18438616290
簡要描述：AS601245 345987-15-7AS601245 is an inhibitor of the c-Jun NH2-terminal kinase (JNK) (hJNK1: IC50=150nM, hJNK2: IC50=220nM and hJNK3: IC50=70 nM), has neuroprotective properties.
產(chǎn)品型號：abs47028003廠商性質(zhì)：生產(chǎn)廠家更新時間：2026-01-12訪 問 量：688產(chǎn)品分類
Product Category相關(guān)文章
Related Articles詳細(xì)介紹
| 品牌 | absin | CAS | 345987-15-7 |
|---|---|---|---|
| 分子式 | C20H16N6S | 純度 | 98% |
| 分子量 | 372.45 | 貨號 | abs47028003 |
| 規(guī)格 | 1mg | 供貨周期 | 現(xiàn)貨 |
| 主要用途 | is an inhibitor of the c-Jun NH2-termin | 應(yīng)用領(lǐng)域 | 化工,生物產(chǎn)業(yè),農(nóng)林牧漁,制藥/生物制藥,綜合 |
AS601245 345987-15-7
| 產(chǎn)品描述 | |
| 描述 | AS601245 is an inhibitor of the c-Jun NH2-terminal kinase (JNK) (hJNK1: IC50=150nM, hJNK2: IC50=220nM and hJNK3: IC50=70 nM), has neuroprotective properties. |
| 純度 | 98% |
| 儲存/保存方法 | Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 別名 | JNK Inhibitor V |
| 可溶性/溶解性 | DMSO ≥35 mg/mL |
| 生物活性 | |
| 靶點 | JNK |
| In vitro(體外研究) | AS601245 inhibits isolated hJNK3 in an ATP-competitive manner. Selectivity of AS601245 is tested against a large panel of kinases. AS601245 exhibits 10- to 20-fold selectivity over c-src, CDK2, and c-Raf and more than 50- to 100-fold selectivity over a range of Ser/Thr- and Tyr-protein kinases. The effects of AS601245 and Clofibrate alone or in association are analysed on proliferation, apoptosis, differentiation and the gene expression profile of CaCo-2 human colon cancer cells. Reduction of cell proliferation, accompanied by the modulation of p21 expression is observed in HepG2 cells, also. 5?μM Clofibrate, 0.1?μM AS601245, and the combined treatment with the two substances do not cause acute toxicity in HepG2 cells. All treatments reduce cell proliferation starting from 48 hours after the beginning of experiments, and the inhibitory effect reaches the maximum at 72 hours. |
| In vivo(體內(nèi)研究) | AS601245 is a potent inhibitor of LPS-induced TNF-α release in mice. Administered orally at 0.3, 1, 3, and 10 mg/kg, AS601245 decreases the TNF-α release in a dose-dependent manner. AS601245 (40, 60, and 80 mg/kg) administered i.p. provides significant protection against the delayed loss of hippocampal CA1 neurons in a gerbil model of transient global ischemia. This effect is mediated by JNK inhibition and therefore by c-Jun expression and phosphorylation. A significant neuroprotective effect of AS601245 administered either by i.p. injection (6, 18, and 60 mg/kg) or as i.v. bolus (1 mg/kg) followed by an i.v. infusion (0.6 mg/kg/h) is also observed in rats after focal cerebral ischemia. |
| 參考文獻 | |
| 參考文獻 |
|
| 研究領(lǐng)域 | |
| 研究領(lǐng)域 | Immunology Neuroscience CancerCancer Metabolism CancerTumor biomarkers Drug DiscoverySmall Molecule DrugLead Compound Discovery |
產(chǎn)品咨詢
地址：上海市浦東新區(qū)新浩路58號申江科創(chuàng)園18棟
郵箱：
傳真：